LA JOLLA, Calif. – Gene therapy has come a long way from using retroviral vectors to insert gamma-chain transgenes into cells of children with severe combined immunodeficiency in the early 1990s, an act that increased the risk of developing leukemia.
LA JOLLA, Calif. – Stem cells offer promising new treatments, but panelists at a session during the annual Stem Cell Meeting on the Mesa warned the audience that the treatments' unique features pose challenges to gaining reimbursement.
The third quarter typically sees fewer venture capital investments than the second quarter – not surprising since it covers prime vacation time. While I'm sure more than one deal has been consummated from the beach, VCs deserve their downtime, too.
Rather than riding off into the sunset after successfully developing a biotech company and getting it sold to a big pharma, many CEOs start anew, trying to show that lightning can strike twice (or more).
Biomedical Advanced Research and Development Authority (BARDA), which evolved out of the biodefense-focused Project BioShield, has moved beyond simply funding drugs and devices that might be used in the event of terrorism.
Biomedical Advanced Research and Development Authority (BARDA), which evolved out of the biodefense-focused Project BioShield, has moved beyond simply funding drugs and devices that might be used in the event of terrorism. The division of the U.S. Department of Health and Human Services now prefers to help develop dual-use products that can have an immediate benefit to public health as well as a guarding against potential terrorism.
Nearly 60 years after tardive dyskinesia (TD) was recognized as a disease, patients may soon have a drug approved to treat their involuntary movements.
More than two years after the Jumpstart Our Business Startups (JOBS) Act was signed into law, Title III of the act, which allows for equity-based crowdfunding from non-accredited investors, still hasn't been implemented by the SEC.
